Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...

The GLP-1 market is huge and growing, and depending on how patients acquire and pay for their therapies, traditional data ...

I think ironically, it's actually forced people to look for direct-to-patient offerings because they're kind of like, I don't ...

The FDA has sent a warning letter to ImmunityBio over "false and misleading" comments made by its executive chairman, biotech ...

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned a filing for its ...

Spanish pharma group Grifols is planning to sell a minority stake in its US business, via an initial public offering, to ...

At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of ...

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to ...

It claims the trackers violate privacy clauses in the US Health Insurance Portability and Accountability Act (HIPAA) and ...

Recent developments in the biopharma AI world include a big financing for Verily, plus news from Zealand Pharma, Latent Labs, ...

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...